Phase II Trial of Carboplatin plus S-1 for Previously Untreated Elderly Patients with Advanced Non-small-cell lung cancer with Wild Type Epidermal Growth Factor Receptor (OLCSG1202)

Trial Profile

Phase II Trial of Carboplatin plus S-1 for Previously Untreated Elderly Patients with Advanced Non-small-cell lung cancer with Wild Type Epidermal Growth Factor Receptor (OLCSG1202)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms OLCSG1202
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 16 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 17 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top